# About Retatrutide Safe — independent research record > Retatrutide Safe is an independent editorial project that publishes summaries of the peer-reviewed research literature on retatrutide (LY3437943). Not a clinic, not a vendor. Retatrutide Safe publishes summaries of the peer-reviewed research literature on the investigational triple agonist LY3437943. ## What this site is Retatrutide Safe is an independent editorial project that publishes summaries of the peer-reviewed research literature on retatrutide (LY3437943). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science. The word "safe" in the domain name is a question being investigated, not a claim being marketed. Retatrutide is an investigational drug. Whether and to what degree it is safe at a given dose, in a given population, over a given duration, is exactly what the TRIUMPH Phase 3 program is designed to determine. This site catalogues the evidence as it accumulates. ## Editorial standards Every quantitative claim on this site is sourced to a primary publication or to a regulated trial registration. Inline citations link to the underlying paper on PubMed, PMC, the publishing journal, or ClinicalTrials.gov. The full citation list lives at [/references](/references) and is updated when new readouts publish. We distinguish carefully between (a) peer-reviewed primary literature (NEJM, Lancet, Nature Medicine, Cell Discovery, Biomolecules), (b) registered trial protocols (the TRIUMPH program on ClinicalTrials.gov), and (c) sponsor-released topline data ahead of peer review (TRIUMPH-1 and TRIUMPH-4 toplines as of 2026). Sponsor toplines are clearly labelled as such and are replaced by the peer-reviewed publication once it appears. We do not write in prescriptive voice. Doses and durations are described as administered in the published trial protocols, not recommended for any reader. Whether retatrutide is appropriate for any individual is a clinical question that belongs between that person and their licensed clinician, in a context where the drug is legally prescribable — and as of 2026 retatrutide is not. ## What this site is not This site is not a clinic, not a pharmacy, and not a vendor. The domain modifier "safe" is editorial framing — a question that the publisher is investigating through the literature, not a description of services offered. We do not provide telemedicine consultations. We do not write prescriptions. We do not supply, manufacture, or sell retatrutide or any other compound. We are not affiliated with the sponsor of any retatrutide trial. No retatrutide product is currently available outside an enrolled clinical trial. Some compounded or grey-market "retatrutide" product sold outside clinical trials has unknown identity, purity, sterility, and dose accuracy. Use outside a regulated trial carries risks that are not characterised in the published literature. This site does not address that market beyond noting its existence and the risks it implies. ## Conflict-of-interest disclosure Retatrutide Safe receives no funding from any pharmaceutical sponsor, contract research organisation, telehealth provider, compounding pharmacy, or peptide vendor. The site carries no advertising. Editorial decisions about what to cover, how to characterise findings, and which trials to summarise are made independently of any commercial party. When a primary source is a sponsor press release rather than a peer-reviewed publication, the source is labelled as such. When a result has been superseded by a later analysis, the later analysis takes precedence and the earlier source is retained for historical context. This site is an independent editorial digest of the publicly available research literature on LY3437943 — not a clinic, not a vendor, not a clinical recommendation. --- A primary-literature monitor for an investigational compound — not a clinic, not a vendor, not a clinical recommendation.